Physician profile
Yolanda Spraggins
NPI 1003882309
$2,487.43
in general payments reported to CMS, 2019-2025
30 companies · $779 in 2025
The $779 reported for 2025 was more than what 97% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $15.63 · 2023: $688 · 2024: $1,005 · 2025: $779.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,472.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,471.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $637.94 | 2023-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $219.01 | 2023-2025 | Qelbree, Qelbree |
| Verrica Pharmaceuticals INC. | $180.29 | 2024 | Ycanth |
| Ironshore Pharmaceuticals INC. | $128.54 | 2023-2024 | Jornay Pm |
| Abbott Laboratories | $110.85 | 2022-2024 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $109.45 | 2023-2025 | Shingrix, Arexvy, Bexsero |
| Merck Sharp & Dohme LLC | $104.18 | 2024-2025 | Gardasil 9, Capvaxive, Gardasil |
| Astrazeneca Pharmaceuticals Lp | $103.40 | 2024 | Tezspire |
| Tris Pharma INC | $97.11 | 2023-2025 | Dyanavel Xr |
| Xeris Pharmaceuticals, INC. | $91.92 | 2023-2025 | Gvoke Hypopen, Keveyis |
| Pfizer INC. | $62.95 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $61.64 | 2024-2025 | |
| Abbvie INC. | $58.29 | 2023 | Ubrelvy, Qulipta |
| Janssen Pharmaceuticals, INC | $51.29 | 2025 | Spravato |
| Sage Therapeutics, LLC | $48.61 | 2024 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $47.21 | 2024-2025 | Valtoco |
| Sanofi Pasteur INC. | $44.75 | 2025 | |
| Exact Sciences Corporation | $37.92 | 2023-2024 | Cologuard Collection Kit |
| Seqirus USA INC | $35.65 | 2025 | Flucelvax, Fluad |
| Collegium Pharmaceutical, INC. | $34.88 | 2025 | Jornay Pm |
| Medtronic, INC. | $30.61 | 2025 | Inceptiv |
| Inspire Medical Systems, INC. | $30.06 | 2023 | Inspire |
| Tolmar, INC. | $25.07 | 2025 | Jatenzo |
| Daiichi Sankyo INC. | $23.91 | 2024 | Injectafer |
| Optinose US, INC. | $23.65 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.93 | 2024 | |
| Vbi Vaccine (Delaware) INC. | $20.02 | 2023 | Prehevbrio |
| Novo Nordisk INC | $16.09 | 2023 | Wegovy |
| Alexion Pharmaceuticals, INC. | $15.15 | 2023 | Strensiq |
| Cipher Pharmaceuticals US LLC | $14.06 | 2025 | Natroba, Spinosad |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yolanda Spraggins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.